论文部分内容阅读
1988年8月起在食管癌高发区鹤壁市郊居民中,采用随机分组双盲对照,对1006名食管轻,重度增生患者进行复合核黄素营养干预研究。在服药15个月后进行了第1次食管细胞学复查。初步结果显示,轻增患者疗效不明显;实验组重度增生好转率略高于对照组,进展率略低于对照组,实验组重增癌变率较对照组减少77.2％(P<0.05)。说明复合核黄素对食管上皮重度增生癌变的抑制作用明显。对重度增生的治疗(逆转)作用也是存在的。
Starting from August 1988 in the outskirts of Hebi, a high-risk area of esophageal cancer, a randomized, double-blind, double-blind study of 1,006 patients with mild or severe esophageal hyperlipidemia was conducted. The first esophageal cytology review was performed 15 months after taking the drug. The preliminary results showed that the effect of lightly increasing patients was not obvious; the rate of improvement of severe hyperplasia in the experimental group was slightly higher than that in the control group, and the progress rate was slightly lower than that in the control group. The cancer-increasing rate in the experimental group increased by 77.2% compared with the control group (P<0.05). This shows that compound riboflavin has a significant inhibitory effect on severe hyperplasia of esophageal epithelium. Therapeutic (reversal) effects on severe hyperplasia are also present.